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Background: The cardiovascular effects of treating older adults with subclinical
hypothyroidism (SCH) are uncertain. Although concerns have been raised regarding a
potential increase in cardiovascular side effects from thyroid hormone replacement,
undertreatment may also increase the risk of cardiovascular events, especially for
patients with cardiovascular disease (CVD).
Objective: To determine the effects of levothyroxine treatment on cardiovascular
outcomes in older adults with SCH.
Methods: Combined data of two parallel randomised double-blind placebo-controlled
trials TRUST (Thyroid hormone Replacement for Untreated older adults with Subclinical
hypothyroidism – a randomised placebo controlled Trial) and IEMO80+ (the Institute for
Evidence-Based Medicine in Old Age 80-plus thyroid trial) were analysed as one-stagen.org May 2021 | Volume 12 | Article 6748411
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Frontiers in Endocrinology | www.froindividual participant data. Participants aged ≥65 years for TRUST (n=737) and ≥80 years for
IEMO80+ (n=105) with SCH, defined by elevated TSH with fT4 within the reference range,
were included. Participants were randomly assigned to receive placebo or levothyroxine, with
titration of the dose until TSH level was within the reference range. Cardiovascular events and
cardiovascular side effects of overtreatment (new-onset atrial fibrillation and heart failure) were
investigated, including stratified analyses according to CVD history and age.
Results: The median [IQR] age was 75.0 [69.7–81.1] years, and 448 participants (53.2%)
were women. The mean TSH was 6.38± SD 5.7 mIU/L at baseline and decreased at 1 year to
5.66 ± 3.3 mIU/L in the placebo group, compared with 3.66 ± 2.1 mIU/L in the levothyroxine
group (p<0.001), at a median dose of 50 mg. Levothyroxine did not significantly change the
risk of any of the prespecified cardiovascular outcomes, including cardiovascular events (HR
0.74 [0.41–1.25]), atrial fibrillation (HR 0.69 [0.32–1.52]), or heart failure (0.41 [0.13–1.35]), or
all-cause mortality (HR 1.28 [0.54–3.03]), irrespective of history of CVD and age.
Conclusion: Treatment with levothyroxine did not significantly change the risk of
cardiovascular outcomes in older adults with subclinical hypothyroidism, irrespective of a
history of cardiovascular disease and age.
Clinical Trial Registration: [ClinicalTrials.gov], identifier [NCT01660126] (TRUST);
Netherlands Trial Register: NTR3851 (IEMO80+).Keywords: cardiovascular disease, levothyroxine, randomised controlled trial, subclinical hypothyroidism, older adultsINTRODUCTION
Subclinical hypothyroidism (SCH) is a common condition in
older adults, with a prevalence between 8% and 18% (1). SCH is
defined by elevated levels of thyroid stimulating hormone (TSH)
with free thyroxine (fT4) within the reference range. Patients
with SCH are mostly asymptomatic, although SCH is a possible
contributor to various health problems including cardiovascular
diseases (CVD) (2). The cardiovascular effect of treating older
adults with SCH is uncertain.
The cardiovascular system is sensitive to changes in thyroid
hormone concentrations due to thyroid hormone receptors in
myocardial and vascular endothelial tissues (3). Associations
have been found between SCH and an increase in the number
of cardiovascular risk factors (4). In addition, meta-analyses of
prospective studies showed that SCH was associated with an
increased risk of heart failure, major adverse cardiovascular
events (MACE) and cardiovascular death (2, 5–7). Although
associations have been found between SCH and CVD, data are
limited and conflicting regarding the effect of treatment with
levothyroxine on cardiovascular outcomes (3). Large randomised
controlled trials (RCT) investigating especially cardiovascularence interval; EQ-5D, EuroQol Group 5-
e; fT4, free thyroxine 4; HR, hazard ratio;
Based Medicine in Old Age 80-plus thyroid
a; RCT, randomised controlled trial; SCH,
dard deviation; SE, standard error; TRUST,
Untreated older adults with Subclinical
placebo controlled Trial; TSH, thyroid
hyroid Related Quality-of-Life Patient-
ntiersin.org 2outcomes in older patients are limited and most often
investigated surrogate markers of CVD, such as cardiovascular
risk factors (8) or cardiac function and structure (9–11). On the
one hand, concerns have been raised regarding a potential
increase in cardiovascular side effects from thyroid hormone
replacement, such as atrial fibrillation and heart failure. On the
other hand, undertreatment may increase the risk of
cardiovascular events, especially for patients with CVD or
older age.
Two recent RCTs, namely TRUST (Thyroid hormone
Replacement for Untreated older adults with Subclinical
hypothyroidism – a randomised placebo controlled Trial) and
IEMO80+ (the Institute for Evidence-Based Medicine in Old Age
80-plus thyroid trial), reported the absence of beneficial effect of
levothyroxine on thyroid specific quality of life related outcomes
in older patients with SCH (12, 13). For the first time combining
all data from the two trials, the aim of the present study is to
assess the effect of levothyroxine treatment on cardiovascular
outcomes in older adults with SCH.MATERIALS AND METHODS
This study is a prespecified combined analysis of the TRUST and
IEMO80+ studies. These studies were designed and executed as
parallel trials with identical study protocols, both investigating
whether levothyroxine provides clinical benefits in older persons
with SCH.
An Institutional Review Board approved the studies prior to
data collection. Written informed consent was obtained from allMay 2021 | Volume 12 | Article 674841
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participant data (IPD) of these two randomised double-blind
placebo-controlled trials. Detailed description and protocols
have been published previously (14, 15). In summary, older
participants (≥65 years for TRUST and ≥80 years for IEMO80+)
with SCH, diagnosed by elevated TSH levels (4.6 to 19.9 mIU/L),
measured on at least two occasions between 3 months and 3
years apart, with fT4 levels within the reference range, were
enrolled in Ireland, Scotland, Switzerland and The Netherlands.
Participants were randomised in a 1:1 ratio for levothyroxine or
placebo, with titration of the levothyroxine dose according to
TSH level every 6 to 8 weeks and a mock titration schedule with a
similar frequency in the placebo group. The levothyroxine group
started with a dose of 50mg daily (or 25mg for participants with
weight <50kg or a history of coronary heart disease). Participants
were followed up for a minimum of 12 months and a maximum
of 36 months between April 2013 and May 2018. The final
follow-up was on May 4, 2018.
Endpoints
The present analysis reports cardiovascular outcomes, including
all-cause and cardiovascular mortality, and both cardiovascular
events and cardiovascular side effects. Cardiovascular events are
fatal and non-fatal cardiovascular events, including acute
myocardial infarction, stroke, amputations for peripheral vascular
disease, revascularisations for atherosclerotic vascular disease
(including for acute coronary syndrome) and heart failure
hospitalisations. Cardiovascular side effects of overtreatment
include new-onset atrial fibrillation and new-onset heart failure.
Secondary outcomes include the cardiovascular parameters blood
pressure, heart rate and weight, which were measured as positive
signals of TSH change.
History of Cardiovascular Disease and Age
Stratified analyses were executed for patients with or without a
history of CVD at inclusion. CVD was defined as ischemic heart
disease (both angina pectoris or myocardial infarction), stroke or
transient ischemic attack, heart failure, peripheral vascular
disease, revascularization or atrial fibrillation. Furthermore,
patients were stratified in the 65 to 80 age range, or ≥80 years old.
Statistical Analysis
Baseline characteristics are presented as mean ± standard
deviation (SD) or median [interquartile range (IQR)] depending
on the distribution of data, stratified for history of CVD. Hazard
ratios (HR) were obtained from a Cox proportional hazard
regression model and were adjusted for country, sex, starting
dose of levothyroxine and study, similar to previous publications
(14, 15). Results at 12 months and between-group differences were
adjusted for country, sex, starting dose of levothyroxine, study
(TRUST or IEMO80+) as random effect and baseline levels of the
same variable with the use of linear mixed models. Between-group
differences are the value in the levothyroxine group minus the
value in the placebo group. The efficacy and safety analyses were
carried out in a modified intention-to-treat population, which
included participants with data on the outcome of interest. The
data were analysed using IBM SPSS Statistics, version 23. P-valuesFrontiers in Endocrinology | www.frontiersin.org 3were considered statistically significant if lower than 0.05.
Interaction analyses were performed between treatment and
history of CVD and all secondary endpoints.RESULTS
In total, all 737 patients from TRUST and all 105 patients from
IEMO80+ were included in this combined data-analysis, see
Figure 1. Of the 842 participants who underwent randomization,
422 were assigned to receive placebo and 420 to receive
levothyroxine. For the baseline characteristics see Table 1. The
median age of the 842 participants was 75.0 [IQR 69.7–81.1]
years, with 419 (56.9%) participants older than 80 years. In total,
448 participants (53.2%) were women and 302 (35.9%) had a
history of CVD. History of CVD or cardiovascular risk factors
did not differ between the placebo or levothyroxine group.
Median follow-up was 17 months. A total of 368 participants
(87.2%) of the placebo group and 363 (86.4%) of the
levothyroxine group completed 12-month follow-up, which did
not differ between patients with or without a history of CVD, see
Figure 1. In total, 194 (23.0%) patients discontinued the trial
regimen and 44 (5.2%) withdrew from follow-up. Most
participants (83.8%) started with a dose of 50 mg and 16.2%
with 25 mg levothyroxine. Of patients with a history of CVD,
58.9% started with a dose of 50 mg levothyroxine and of patients
older than 80 79.5%.Thyroid Function
The mean ± SD TSH was 6.38 ± 5.7 mIU/L at baseline, and
decreased at 1 year to 5.66 ± 3.3 mIU/L in the placebo group,
compared with 3.66 ± 2.1 mIU/L in the levothyroxine treated
group (p<0.001), at a median dose of 50 mg. TSH did not differ
significantly at baseline or at 12 months between patients with or
without a history of CVD (p-interaction=0.31), see Table 2.Cardiovascular Outcomes
In total, 44 (5.2%) fatal and non-fatal cardiovascular events
occurred after a median follow-up of 17 months, which did
not significantly differ between placebo and levothyroxine with a
HR comparing treatment to placebo of 0.74 (0.41 to 1.35).
Comparing cardiovascular side effects of overtreatment risk of
new-onset atrial fibrillation was associated with levothyroxine
treatment was HR 0.69 (0.32 to 1.52) and HR of new-onset heart
failure was 0.41 (0.13 to 1.35). Furthermore, in total, 21 (2.5%)
deaths from any cause occurred (of which 4 cardiovascular
deaths) with a HR for levothyroxine treatment of 1.28 (0.54 to
3.03). Figure 2 shows a forest plot of all cardiovascular outcomes,
comparing placebo to levothyroxine stratified by history of CVD
and age, showing that levothyroxine did not significantly change
the risk of any of the cardiovascular outcomes, irrespective of
CVD history or age (p for interaction all >0.10).
No clinically relevant or statistically significant adjusted
differences between levothyroxine and placebo were found at
12 months for blood pressure, heart rate and weight (Table 2).May 2021 | Volume 12 | Article 674841
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history of CVD (p for interaction all >0.10).DISCUSSION
In this prespecified combined analysis of the TRUST and
IEMO80+ trials, treatment with levothyroxine did not increase
or decrease the risk of cardiovascular outcomes significantly in
older adults with SCH, irrespective of CVD history and age.
In older patients with SCH, the current European and United
States guidelines recommend no routine thyroid hormone
therapy (16, 17). Especially in older people, treatment should
be individualised, gradual and closely monitored. In the oldest
old subjects, defined as >80 years old, SCH should be carefully
followed with a wait-and-see strategy, generally avoiding
hormonal treatment (16). The outcomes of both TRUST and
IEMO80+ support this wait-and-see strategy as they showed no
consistent beneficial effect of levothyroxine on quality of life, in
both older (TRUST) and oldest old subjects (IEMO80+) (12, 13).
Although experts have pointed out the need, before the TRUST
and IEMO80+ studies, randomised trials investigating hard
cardiovascular endpoints were lacking (18). Hence we sought
to answer the question whether undertreatment may cause
cardiovascular events or treatment may cause cardiovascularFrontiers in Endocrinology | www.frontiersin.org 4side effects. We found no significant adjusted differences in
cardiovascular parameters and neutral results for all
cardiovascular outcomes with wide confidence intervals,
although all point estimates were favourable for levothyroxine
treatment. Therefore, we found no evidence to support any
major short to medium term harmful effect on cardiovascular
events of levothyroxine treatment for subclinical hypothyroidism
in older people, including in those with known prior
cardiovascular disease.
Taken together, our finding that treatment with levothyroxine
did not change the risk of all cardiovascular outcomes in older
adults with SCH is of incremental value to the limited existing
literature. We showed that when treatment with levothyroxine is
indicated on an individual basis, treatment should not be initiated
especially to prevent cardiovascular events, nor should it be
withheld because of potential cardiovascular side effects,
irrespective of CVD history. Provided that treatment should be
carefully monitored and titrated over time, as was in the trials.
Strengths and Limitations
This is a unique combined data analysis of the two largest RCTs
to date investigating cardiovascular outcomes in older patients
with SCH. Some limitations should be mentioned.
First, it was initially planned in both TRUST and IEMO80+
that cardiovascular events were to be a primary outcome
together with thyroid-specific quality of life. Owing to delaysFIGURE 1 | Flowchart study population. Combined data of the TRUST and IEMO80+ trials will be examined as one-stage individual participant data of these two
randomised double-blind placebo-controlled parallel group trials. Cardiovascular disease (CVD) is defined as ischemic heart disease, stroke or transient ischemic
attack, heart failure, peripheral vascular disease, revascularisation or atrial fibrillation. Median follow-up was 17-months.May 2021 | Volume 12 | Article 674841
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apparent that both studies would be underpowered for this
aspect (13). However, the studies combined enabled the largest
data analysis thus far regarding this subject and it is unlikely
that a similar experiment will be successful in the near future,
especially not a large one. Overall incidence of cardiovascular
outcomes after a median follow-up of 17 months in the
patients with SCH was still relatively low, only 44 (5.2%)
patients had a fatal or nonfatal cardiovascular event.
However, 17 months is still relatively short, and does not
exclude a substantial cardiovascular 10-year risk. Second, the
limited power hampered us to further stratify according to
history of CVD and to distinguish between patients with
ischemic heart disease, patients with heart failure or patientsFrontiers in Endocrinology | www.frontiersin.org 5with vascular disease e lsewhere in the body (e .g .
cerebrovascular or peripheral artery disease). Furthermore, of
the 252 patients with a history of CVD, only 38 subjects had a
history of heart failure. Third, of all included older
participants, only 251 (29.8%) defined as the oldest old (≥80
years old). Fourth, mean TSH level was not very high at
baseline in the total population (6.4 ± 2.0). Fifth, with
respect to ethnicity the study population was predominantly
white (98%).
Conclusions
Treatment with levothyroxine did not significantly change the
risk of cardiovascular outcomes in older adults with subclinical
hypothyroidism, irrespective of a history of CVD.TABLE 1 | Baseline characteristics (n = 842).
Characteristic No history of CVD History of CVD
Placebo (n = 271) Levothyroxine (n = 269) Placebo (n = 151) Levothyroxine (n = 151)
Age (years), median [IQR] 72.7 [68.6-79.2] 73.6 [68.9-78.8] 79.9 [73.0-84.5] 76.8 [72.0-81.7]
Female sex, n (%) 162 (59.8) 161 (59.9) 62 (41.1) 63 (41.7)
Caucasiana, n (%) 264 (97.4) 264 (98.1) 150 (99.3) 150 (99.3)
Standard housingb, n (%) 264 (97.4) 262 (97.4) 142 (94.0) 145 (96.0)
History of cardiovascular disease, n (%)
Ischemic heart diseasec 62 (41.1) 63 (41.7)
Stroke or transient ischemic attack 55 (36.4) 33 (21.9)
Peripheral vascular disease 15 (9.9) 20 (13.3)
Revascularisation 46 (30.5) 59 (39.1)
Heart failure 23 (15.2) 15 (9.9)
Atrial fibrillation 53 (35.3) 58 (38.9)
Cardiovascular risk factors, n (%)
Hypertension 115 (42.8) 133 (49.4) 92 (61.3) 86 (57.0)
Diabetes mellitus 29 (10.7) 40 (14.9) 28 (18.7) 30 (19.9)
Current smoking 25 (9.2) 19 (7.1) 10 (6.6) 13 (8.6)
Former smoking 105 (38.7) 112 (41.6) 76 (50.3) 74 (49.0)
Number of concomitant medicines 3 [1-5] 3 [1-5] 6 [4-6] 6 [4-8]
Clinical parameters
Body mass index (kg/m2) 27.2 ± 4.6 27.8 ± 5.2 28.5 ± 4.5 28.5 ± 5.4
Waist circumference (cm) 95.7 ± 12.9 97.1 ± 12.4 100.8 ± 11.4 100.9 ± 12.4
Blood pressure (mmHg)
Systolic 142 ± 20 143 ± 18 142 ± 20 140 ± 21
Diastolic 75 ± 12 75 ± 11 73 ± 12 72.3 ± 10
Heart rate (beats per min.) 70.4 ± 10.6 69.1 ± 10.6 68.6 ± 13.0 67.6 ± 12.7
Hand-grip strength (kg) 27.3 ± 10.5 27.2 ± 10.3 27.3 ± 11.9 28.5 ± 10.3
Thyroid functiond
Thyrotropin (mIU/liter) 6.4 ± 2.1 6.5 ± 2.1 6.2 ± 1.8 6.2 ± 1.7
Median 5.7 [5.1-7.0] 5.7 [5.2-7.0] 5.7 [5.0-6.8] 5.7 [5.0-6.8]
Free thyroxine (pmol/liter) 13.1 ± 1.9 13.4 ± 2.0 14.0 ± 2.0 13.7 ± 2.2
Quality of lifee
Hypothyroid Symptoms score 15.4 ± 16.9 17.5 ± 19.2 21.0 ± 20.4 18.9 ± 18.2
Tiredness score 23.0 ± 18.2 25.7 ± 20.7 29.6 ± 22.5 25.5 ± 20.6
EQ-5D descriptive index 0.855 ± 0.18 0.847 ± 0.18 0.804 ± 0.20 0.819 ± 0.22
EQ visual-analogue scale score 77.6 ± 15.9 79.2 ± 15.2 73.3 ± 15.3 76.0 ± 15.1May 2021 | VoValues are mean ± standard deviation (SD) or median [interquartile range (IQR)]. Cardiovascular disease (CVD) was defined as ischemic heart disease (both angina pectoris or myocardial
infarction), stroke or transient ischemic attack, heart failure, peripheral vascular disease, revascularization or atrial fibrillation. aRace was reported by the patient. bStandard housing was
defined as non-sheltered community accommodation. By contrast, sheltered housing is purpose built grouped housing for older persons, often with an on-site manager or warden.
cIschemic heart disease was defined as a history of angina pectoris or previous myocardial infarction. d To convert the values for free thyroxine to nanograms per deciliter, divide by 12.87.
eThe Hypothyroid Symptoms score and the Tiredness score from the Thyroid-Related Quality of Life Patient-Reported Outcome (ThyPRO) questionnaire are each assessed on a scale
from 0 to 100, with higher scores indicating more symptoms and tiredness, respectively. The minimum clinically important difference for each score has been estimated as 9 points. The
EuroQoL [EQ] Group 5-Dimension Self-Report Questionnaire (EQ-5D) scores included both the EQ5D descriptive index (on a scale from −0.59 to 1.00) and the score on the EQ visual-
analogue scale (on a scale from 0 to 100); higher scores on each scale indicate better quality of life.lume 12 | Article 674841
Zijlstra et al. Subclinical Hypothyroidism and Cardiovascular OutcomesTABLE 2 | Thyroid function and cardiovascular parameters at 12 months for patients with or without a history of cardiovascular disease*.
Variable No history of CVD History of CVD
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5.7 [5.2 to 7.0] 4.9 [4.6
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0.7




67.6 ± 1.0 68.7 ±
1.2








76.3 ± 0.9 75.0 ±
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80.1 ± 1.4 79.7 ±
1.3
80.6 ± 1.5 0.27
(−0.67 to
1.21)
0.83Frontiers in Endocrinology | www.frontiersin.org 6 May 2021 | Volume 12 | Article 67Values are mean ± standard error (SE). CI, confidence interval; CVD, cardiovascular disease. Results at 12 months and between-group differences are adjusted for stratification variables
(country, sex, starting dose of levothyroxine and study as random effect) and baseline levels of the same variable with the use of linear mixed models. Between-group differences are the
value in the levothyroxine group minus the value in the placebo group. Interaction analyses were performed between treatment and history of CVD and all endpoints. *CVD was defined as
ischemic heart disease (both angina pectoris or myocardial infarction), stroke or transient ischemic attack, heart failure, peripheral vascular disease, revascularization or atrial fibrillation.FIGURE 2 | Cardiovascular outcomes stratified for history of cardiovascular disease and age. Cardiovascular disease (CVD) is defined as ischemic heart disease,
stroke or transient ischemic attack, heart failure, peripheral vascular disease, revascularisation or atrial fibrillation. Hazard ratios for treatment were obtained from a
Cox proportional hazard regression model predicting and were adjusted for study, country, sex and starting dose of levothyroxine.4841
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